# A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

> **NCT05543187** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 5 (actual)

## Conditions studied

- Progressive Familial Intrahepatic Cholestasis (PFIC)

## Interventions

- **DRUG:** TAK-625

## Key facts

- **NCT ID:** NCT05543187
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2023-09-04
- **Final completion:** 2025-07-22
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05543187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05543187, "A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05543187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*